

Keyword Index for Volume 107

- 15-PGDH 707, 1514
25-hydroxyvitamin D 1589
2D:4D 1631
5-ALA 462
5-aza-2'-deoxycytidine 1116
5-fluorouracil 435
5FU toxicity 1525
6th vital sign 617
- α -carotene 1580
accelerated-failure time 531
active surveillance 1467
activin 1978
activin receptor 1978
acute pain 937
ADAMs 143
adenocarcinoma 143
adenocarcinoma *in situ* 1451
adenovirus 448
adherence to therapy 904, 1249
adhesion 129
adjuvant chemotherapy 1257, 1678
adult height 165
advanced NSCLC 442
advanced urothelial carcinoma 1031
adverse event 612
afibercept 598, 604
Africa 1624
age at first birth 564
AhR 43
AIS 1451
Akt 847
Akt1 713
albumin 275
alcohol consumption 234, 537, 879
alternative transcript use 1409
ambulatory patients 1244
amino-acid transporter 632
AML 108
amplification 1997
anal carcinoma 1864
anastrozole 1815
angiogenesis 598, 604, 700, 977, 1207, 1227, 1481, 1498,
angiogenesis inhibitors 455
angiogenic factors 501
animal models 1944
anthracyclines 1257
anticancer drugs 1100, 1797
anti-EGFR antibody 340
antitumour activity 53
anti-vascular therapy 469
anti-VEGF antibody 308
anti-VEGF therapy 598
anxiety 1459, 1644
apolipoproteins 1883
apoptosis 63, 469, 1518
artemis overexpression 1506
Asian 1075
- aspirin 1514, 1602
ATR 291
atrophic gastritis 888
autopsy 1
axitinib 1268, 1277
AZD8055 1093
- BARD1 isoforms 675
basal core promoter mutant 2010
basement membrane 1153
BCAR4 947
 β -carotene 1580
 β -catenin 1144, 1514
Bcl-2 1714
BCL2 967
benefits and risks 1938
benign tumours 1761
bereavement 544
beta1 integrin 1969
bevacizumab 287, 360, 658, 961, 1481
BI 2536 280
bicalutamide 1714
 β III- β V-tubulin 823
bilateral breast cancer 549
biomarker 71, 508, 823, 840, 1009, 1031, 1354, 1384, 1518, 1729, 1754, 1883, 1987
biomarker mRNA 150
bisphosphonates 7, 1665
bladder cancer 116, 123, 469, 477, 1384, 1392, 1826
body mass index 169, 1608
bone 63, 1547
bone marrow endothelial cells 1737
bone marrow stroma 1737
bone matrix 713
bone metastases 646, 1665
bortezomib 1844
brain metastases 1454, 1075
brain-only metastatic behaviour 1454
BRCA1 675, 2005
BRCA1/2 mutation 24
BRCA2 2005
breast biomarkers 382
breast cancer 7, 12, 18, 24, 63, 71, 75, 129, 230, 375, 527, 724, 732, 748, 793, 800, 874, 947, 956, 1175, 1239, 1257, 1459, 1584, 1608, 1631, 1722, 1815, 1892, 1901, 2016
breast cancer risk 176
breast cancer subtypes 1454
breast cancer surgery 937
breast masses 224
breast surgery 1459
Breslow thickness 570
- C75 300
caffeine 874
- calcium channels 375
calibration 1025
calprotectin 1876
CALYPSO 588
cancer cells 1337
cancer clinical trials 1017
cancer prevalence 1195
cancer progenitors 43
cancer registration 1159
cancer screening 1938
cancer therapy 1207
cancer vaccine 1302
capecitabine 585, 1268, 1678
carbonic anhydrase IX 1131
carboplatin 442, 588, 1310
carcinoembryonic antigen-related cell adhesion molecule 1745
carcinoma 739
carotenoids 1580
case-control study 1589, 1644
castration-resistant 592
CD31 1044
CD98 632
CDK 516
CEA 266, 724
CEBPD 732
CECs 1564
cell cycle 1083
cell death 469
cell fraction 1345
cell lineage 2016
cell-cycle arrest 516
cellular radiosensitivity 1506
CEPs 1564
cervical cancer 243, 556, 918, 1445, 1574, 1917, 1956
cervical neoplasia 1624
cervical screening 243
cervix 739
cetuximab 626, 1932
chemokine 1729
chemokines/receptors 1944
chemotaxis 713
chemotherapy 7, 31, 158, 531, 549, 840, 1100, 1107, 1277, 1327, 1637, 1826
Chernobyl 994
chick chorioallantoic membrane assay 1853
childhood 183
childhood cancer 544, 1159, 1652
childhood cancer survivors 234
childhood leukaemia 1159, 1163, 1652
childhood obesity 169
choriocarcinoma 1969
chromosome instability 71
chromosome translocation 739
chronic myeloid leukaemia 904
CIN 1451
- circulating endothelial cells (CEC) 1286
circulating tumour cells (CTC) 448, 1286
circumferential resection margin 1925
cirrhosis 195, 2010
cisplatin 31, 360, 604, 967, 1853
CK19 724
classical CMF 1257
cleaved tRNA 1987
clinical trials 808, 910, 1017, 1672
clonality 2016
cluster analysis 234
coffee 874
cohort 195, 1181
collagen type IV 1153
colon cancer 352, 1169, 1678, 1944
colonoscopy 417, 765
colonoscopy/*methods 1051
colorectal cancer 189, 260, 287, 340, 345, 417, 626, 667, 675, 757, 765, 831, 931, 1001, 1037, 1044, 1518, 1525, 1584, 1602, 1729
colorectal cancer mortality 255
colorectal cancer prevention 1514
colorectal cancer screening 1295
colorectal neoplasm 150, 417, 1051
combination antiretroviral therapy 1624
combination treatment 1692
co-morbidity 189, 1175, 1901
conditional power 910
CONFIRM 1044
connexin-26 1963
continual reassessment method 1022
contralateral breast cancer 221
contralateral testicular germ cell tumour 1637
copper 1488
costs 1574
COX-2 inhibitor 707
C-reactive protein 275, 1031
creatine kinase 1797
CRP 1131
cryotherapy 772
CT genes 116
cumulative incidence 1637
curcumin 1083
CXCR4 43, 491
CXCR7 antagonists 1944
CYC3 1692
cyclin D1a 1684
cyclin D1b 1684
cyclins 516

- cyclodextrin 1083
 cyclooxygenase 207
 CYP2D6 polymorphism 230
 cytokine 639, 1729
 cytology 1384
- daytime napping 527
 DCIS 1451
 debulking surgery 1069
 decision curve analysis 1031
 decision tree analysis 1025
 deep vein thrombosis 1244
 defective DNA repair 1506
 degradation 684
 degradome 143
 delayed diagnosis 1159
 demographics 1810
 dental health 888
 depression 1644
 deprivation 765
 developing countries 1445
 diabetes 1608
 diagnosis 260, 1220, 1876
 diagnostics 1987
 diet 537
 dietary cadmium 895
 differential splicing 675
 digit ratio 1631
 direct sequencing 626
 discrimination 1025
 disease outcome 370
 disseminated tumour cell 1345
 disulfiram 1488
 DJ-1 1595
 DLBCL 491
 D-loop 2016
 DNA double-strand break repair 1776
 DNA hypomethylation 1116
 DNA microarray 1433
 Doc 814
 docetaxel 435, 1233, 1268, 1474
 dose banding 1100
 dose escalation 1022
 dose standardisation 1100
 dose-response relationship 1188
 dosing regimen 455
 doxorubicin 37
 DPD 1950
 drug resistance 1399
 dysregulated pathways 1722
- early breast cancer 1249
 EDTA 1310
 education 189
 EGFR 1864
 EGFR inhibitor 1745
 elastography 224
 elderly 570
 emergency 1220
 EMMPRIN 667
 EMT 707
 endocrine therapy 549, 1249
 endometrial cancer 84, 169, 370, 1997
 endothelial cell 1207
 EORTC 1
- Ephrin A2 1737
 epidemiology 176, 183, 195, 874, 895, 1188, 1451, 1652, 1901
 epidermal growth factor receptor (EGFR) 1745
 epigenetics 75, 375, 1423
 epirubicin 71, 1257
 epithelial ovarian cancer 1783
 epithilones 808
 ERBB2 947
 ERCC1 1950
 erlotinib 1820
 erythropoietin 1317
 erythropoietin receptor 1317
 ESCC 1233
 estrogen receptor signalling 1722
 ethics 1022
 ethnic minorities 1017
 ethnicity 1908
 EVX1 100
 exact tests 1801
 exon arrays 1409
- faecal immunochemical test 1295
 faecal occult blood testing 255
 FAK 856
 fatty acid 129
 fatty acid synthase 300, 977
 female breast cancer 165
 fetal haemoglobin 477
 fetal haemopoiesis 477
 FFA2/FFAR2/GPR43 1337
 FFPE 684
 fibroblast growth factors 1327
 fine-needle aspirates 1354
 fixed dose 1100
 flexible sigmoidoscopy 1295
 fluorescent *in situ* hybridisation (FISH) 71
 FOBT 1938
 FOLFOXIRI 1932
 FOXM1 1766
 fertility analysis 910
- G2-M cell-cycle phase 1766
 gambogic acid 1702
 gastric adenocarcinoma 1125
 gastric cancer 31, 137, 143, 275, 1584, 1595, 1908
 GBM stem-like cells 1488
 gemcitabine 411, 442, 1083, 1488
 gene amplification 325
 gene expression 994, 1433
 gene expression microarray 508
 gene expression profiling 91, 1116
 genetic alterations 1418
 genetics 748
 genomic biomarker 340
 genomic profile 1418
 geographical differences 1595
 germ cell tumour 1833
 gestational trophoblastic tumours 1810
- GFP 448
 GIST 1433
 Gleevec 592
 glioblastoma 1481
 glomerular filtration rate 1310
 GPRD 1602
 granulocyte colony-stimulating factor 814
 GRIA2 91
 gut microbiota 1337
 gynaecological cancers 448
- hand-foot syndrome 585, 1678
 HbF 477
 HBV DNA levels 2010
 HBV genotypes 2010
 head and neck cancer 1138
 health behaviour 201, 234
 health inequalities 183
 hematopoietic stem cells 1302
 hemodynamic response imaging 658
 heparins 1244
 hepatocellular carcinoma 988, 1672, 2010
 HER2 800, 956, 1302
 HER2-positive 793
 HER2-positive breast cancer 1075
 hereditary non-polyposis colorectal cancer 1783
 heterogeneity 1392
 HGF 793
 high-resolution melting analysis 1864
 histology 165
 histone methylation 315
 HIV 1624
 HIV/AIDS 556
 HNSCC 707
 Hodgkin's disease 531
 homologous recombination deficiency 1776
 hookah 1618
 hormone naïve prostate cancer 1554
 hormone receptor 7
 hormone refractory 592
 hormone status 864
 hormones 1631
 hospital admissions 1213
 host cells 1345
 hot flushes 230
 HPV 1917
 HPV infection 482
 HPV vaccination 1445
 HRMA 626
 Hsp27 63
 huachansu 411
 human chorionic gonadotropin 1969
 human glioblastoma 462
 human immune system mice 1302
 human papillomavirus 243, 556, 1574, 1624
 humans 1051
 hypercapnia 658
 hyperoxia 658
- hypertension in pregnancy 176
 hypoxia 291, 516, 1714
- IHC 1684
 IL-12 1302
 IL-12p40 1956
 IL-6 1956
 imaging 224
 imatinib 592, 1433
 immune suppression 1869
 immunocytochemistry 1384
 immunoeexpression 370
 immunohistochemistry 84, 325, 1745, 1864
 immunoproteasome 53
 immunotherapy 116, 1116
 incidence 575, 1159, 1644, 1908, 2005,
 Indonesia 772
 infection 931, 1163
 inflammation 1534
 inflammation-based prognostic score 988
 inhibin B 1833
 inhibitor 53
 INRG 1418
 integrin $\alpha_v\beta_3$ 713
 integrins 847
 interviews as topic/methods 1051
 inulin-type fructans 1337
 invasion 129, 713, 739, 1374, 1969
 irinotecan 435
 ITGA9 1374
- K-ras* 1864
 KDR 1044
 Ki-67 632
 KRAS 340, 1997
 KRAS 626
 KRAS mutation testing 345
- lactate dehydrogenase 422
 laminin 1153
 lapatinib 956, 1075
 LAT1 632
 late effects 1833
 leg length 165
 length of stay 931
 letrozole 1815
 leukaemia 879
 life expectancy 778
 lifestyle 201
 lipoprotein lipase 739
 liver cancer 195, 334
 liver perfusion 658
 living alone 189
 LMP2 53
 LNCaP 1714
 loss of heterozygosity 1776
 low grade 575
 low-income countries 183
 luminal membrane expression 137
 lung adenocarcinoma 1745
 lung cancer 442, 1083, 1188, 1361, 1534, 1584, 1820

- lymphadenectomy 785
 lymphangiogenesis 700
 lymphatic metastasis 150
 lymphocytes 695, 864
 lymphoma 879
- M30 1286
 macrophage migration
 inhibitory factor 1498
 magnetic resonance imaging
 24
 malignant glioma 1481
 malignant PE 1876
 malignant tumours 1761
 mammographic density 18
 mammography 24
 mass screening/methods 1051
 mathematical modelling 814
 MCM-2 1384
 mechanistic PK/PD 814
MED12 1761
 medulloblastoma 1144, 1399
 melanoma 422, 455, 570, 977,
 1498
 men 201
 meningioma 1702
 menopausal hormone therapy
 1181
 mesothelin 137
 mesothelioma 161, 1107, 1978
 MET 325
MET 793
 meta-analysis 1163, 1608
 metabolism 1207
 metachronous cancer 221
 metaplasia–adenoma–
 carcinoma sequence 1125
 metastasectomy 422
 metastasis 63, 75, 129, 360, 375,
 707, 724, 732, 977, 1059,
 1302, 1547, 1678, 1737, 1944,
 1963
 metastasised colorectal cancer
 961
 metastatic breast cancer 1454
 metastatic colorectal cancer
 1932, 1950
 methotrexate resistance 1810
 methylation 100, 732, 1423
 microarray 91, 684, 1361
 microRNA 123, 352, 684, 1345,
 1754, 1987
 microvessel density 334
 middle-income countries 183
 MIF 1498, 1595
 migration 1317, 847
 miR-126 700
 miR-204 967
 miRNA 1361
 miRNA-21 1169
 miRNAs 1354
 mismatch repair 1399
 mismatch repair genes 1783
 mitochondria DNA 2016
 mitotic inhibitor 1692
 mixed lineage leukaemia 315
 MLH1 1783
 MLL4 315
- MLL-antisense 315
 MMP-9 1554
 MMPs 143
 molar pregnancy 1810
 molecular biomarkers 1069
 molecular diagnostics 345, 1138
 molecular subtypes 18, 382
 mortality 1901
 mother 544
 MSH2 1783
 MSH6 1783
 mTOR inhibitors 1093
 multiple myeloma 1844
 multiplex bead assays 287
 mutation 1997
 mutation screening 1761
 Myc 1144
 myelodysplastic/myeloprolif-
 erative neoplasms 879
 myeloma 1987
- NAC1 300
N-acetylglucosaminyltrans-
 ferase-IV 1969
 nasopharyngeal carcinoma 1580
 nass 1618
 National Cancer Institute 1950
 national registries 176
 NCAD 1374
 NEAT 1257
 neoadjuvant 7
 neoadjuvant chemoradio-
 therapy 1925
 neoadjuvant chemotherapy
 1233, 1892, 1925
 neoadjuvant therapy 956, 961
 neoplasm staging 150
 neuroblastoma 967, 1409, 1418
 neuronal differentiation 1144
 neutropenia 814
 neutrophil 695
 NF κ B 1488, 1554
 NGR-hTNF 37
 nomogram 918, 1031, 1467, 1826
 noncancerous tissues 1963
 non-Hodgkin lymphoma 1423
 non-sentinel lymph node 1239
 non-small cell lung cancer 823,
 1107, 1277, 1361, 1474
 non-steroidal anti-inflamma-
 tory drugs 207
 normal tissue radiation injury
 748
 North America 1917
 Notch 1207, 1374
 novel sequence 388
 NSAID 1602
 NT5E 75
 NTRK2 967
 nuclear factor- κ B 652
 nuclear receptor 831
 nutrients 1580
- obesity 169
 oesophageal adenocarcinoma
 564, 1766
 oesophageal cancer 143, 1584,
 1618, 1908, 1925
- oesophageal neoplasm 888
 oesophagectomy 1925
 oesophago-gastric cancer 435
 oestrogen receptor β 831
 oestrogen receptor status 165
 omega-6 1737
 oncology trial 1
 oncology 695, 1022, 1801
 one-step nucleic amplification
 assay 1239
 optimisation 814
 oral hygiene 888
 oral squamous cell carcinoma
 700
 orlistat 977
 osteonecrosis of the jaw 1665
 osteopontin 840, 1131
 outcome 1392, 1665
 ovarian cancer 37, 360, 785, 925,
 1069, 1181, 1327, 1776, 1869
 ovarian clear cell carcinoma 300
 ovarian serous adenocarcinoma
 91
 overall survival 266, 588, 1454
 oxaliplatin 340, 1950
 OxCap 1037
 OxFU 1037
- p16 cellular localisation 482
 p53 334, 516
 paclitaxel 31, 1268, 360, 588,
 823, 1692
 Paget's disease 646
 palliative chemotherapy 442
 PAM 1409
 pancreatic cancer 280, 411, 501,
 632, 1354, 1692, 2005
 pancreatic head cancer 1153
 pancreatic neoplasms 1883
 pancreaticoduodenectomy 1883
 paracentesis 925
 parity 564
 paternal occupation 1652
 paternity 1833
 pathology 1467
 pathways 1220
 patterns of metastasis 221
 Pax8 370
 pazopanib 639
 PCR 116, 1392
 PDGFR β 1702
 pegylated liposomal doxo-
 rubicin 588
 pemetrexed 604
 pepsinogen 888
 performance 1025
 periampullary cancer 1153
 peroxisome biogenesis factor-5
 739
 persistence 1249
 persistent pain 1459
 personalised therapy 1820
 PGE₂ 1514
 PGT 707, 1514
 pharmacokinetics 429, 455, 604,
 1277, 1525
 phase I 604, 1022, 1093
 phase I oncology trials 1025
- phase I study 429, 612, 1474
 phase II 280, 808
 phase II design 1801
 phase II study 1474
 pHH3 84
 photoreaction 1534
 pI κ B α 1554
 PIM kinases 491
 plasma cell neoplasms 879
 plasma cells 864
 platelet lymphocyte ratio 1525
 platelets 1564
 platinum 1637
 platinum drugs 1327
 platinum-sensitive 588
 PleureX 925
 PLK1 1766
 Plk1 inhibitor 280
 polyADP-ribosylation 1317
 polymorphism 1840
 population mixing 1163
 population study 1169
 population-based 12, 161, 570
 postmenopausal 1815
 postoperative pain 937
 pre-clinical cancer 527
 precore mutant 2010
 prediction 1009, 1409, 1826
 prediction model 918
 predictive biomarkers 675,
 1233, 1547
 predictive factor 1892
 prednisone 808
 preeclampsia 176
 pregnancy 176
 preinvasive lesions 1451
 prenatal hormones 1631
 prenatal stress 544
 prevention and control 1051
 primary care 1213, 1644
 primary central nervous system
 lymphoma 1840
 primary ductal invasive breast
 cancer 864
PRKCZ 388
PRL-3 352
 profiling 684, 1433
 prognosis 84, 100, 150, 108, 116,
 334, 422, 508, 639, 695, 831,
 918, 1107, 1131, 1138, 1153,
 1418, 1433, 1454, 1518, 1637,
 1672, 1883, 1997
 prognostic biomarker 370, 667
 prognostic factors 161, 632,
 1009, 1227
 prognostic marker 1169
 prognostic model 800
 prognostic score 275
 progression 1059, 1392
 projections 1195
 proliferation 508
 Prolyl hydroxylases 1423
 propionate 1337
 prospective cohort 831, 895
 prostate cancer 100, 207, 388,
 575, 592, 646, 652, 713, 778,
 840, 847, 895, 1467, 1547,
 1564, 1584, 1714, 1737, 1963

- prostatectomy 1963
 prostatic neoplasms 808
 proteomics 1820
 PSA 100
 psychological factors 937
 pyridoxine 585
 pyrophephorbide-a 1534

 Qcancer 260
 qRT-PCR 1354
 quality of life 904, 1295
 quantitative RT-PCR 150

 RAD001 resistance 847
 radiation 291, 308, 652, 994
 radical cystectomy 1826
 radical prostatectomy 1467
 radiosensitizers 469
 radiotherapy 531, 549, 840, 1361
 randomised trial 585, 1917
 RB 516
 RCC 1131
 reactive oxygen species 1488
 rectal cancer 266
 recurrence 1138
 recurrent ovarian cancer 588
 reduced tumour burden 501
 referral 1220
 rehabilitation care 931
 relative risk 888
 renal cancer 856, 1131, 1227, 1286
 renal cell carcinoma 1009, 1059, 1665
 renal function 1037
 replication 291
 residual cancer 1138
 resistance 1853
 reverse causation 527
 rhabdomyosarcoma 1374
 risk 549
 risk factors 1459
 risk prediction 260
 route 1220
 RPN2 1233
 rs2736100 1001
 RUNX2 1714

 S-1 1474
 S-1 31
 S100 422
 S100A4 667
 sample size 1801
 sarcopenia 931
 Scotland 575
 screening 24, 417, 757, 765, 778, 1917
 screening for distress 617
 screening tool 1459
 screen-specific anxiety 1295
 second malignancies 531
 second-look surgery 785
 secreted SEMA5A 501
 semaphorin 501
 seminoma 1754
 sensitivity and specificity 24
 sentinel lymph node 724
 serum 956, 1729
 serum biomarkers 287, 1820
 serum miRNAs 1987
 sex hormone 564
 sex steroids 831
 shear wave 224
 short term survival 1244
 side effects 158
 signalling 1317
 silica 1188
 silver *in-situ* hybridisation 325
 simulation 1801
 single-visit approach 772
 sitting height 165
 skin 1678
 skin rash 1797
 sleep disturbance 527
 SMAD signalling 1978
 small cell lung cancer 1361
 smoking 234, 537, 879, 1618
 snoRNA 684
 social class 1652
 social support 189
 socio-economic deprivation 1213
 socioeconomic factors 12
 socio-economic inequalities 575
 socioeconomic status 189, 765
 soft-tissue sarcomas 639, 1374
 solid tumours 1268, 1277
 somatic mutation 1761
 sorafenib 455, 592, 1820
 spermatogenesis 1833
 Src 856
 Src kinase 856
 stage II 1169
 staging 12, 1672
 standard chemotherapy 108
 STAT3 352
 statistical analysis 508
 stomach neoplasm 325, 537
 structural variant 388
 sub-Saharan Africa 556
 subtypes 895
 sufficient life expectancy 1025
 sunitinib 1286
 surgery 840, 918, 931, 1175
 survival 91, 161, 275, 300, 334, 537, 757, 864, 874, 918, 1672, 1722, 1840, 1883, 1059, 1075, 1220, 1327, 2005
 survival analysis 531, 695
 survival prediction 1031
 survivin 84
 survivors 1195
 survivorship 1195
 symptoms 904
 systematic review 243

 T cells 1107, 1869
 T1-3 N0 1826
 tamoxifen 230
 tamoxifen resistance 43, 947
 tandutinib 1702
 target population 1445
 target validation 53
 targeted therapy 947, 1227, 1665, 1978
 TAS-102 429
 tea 874
 telomerase 448, 1844
 telomerase regulation 1844
 telomere 1844
 telomere length 1525
 temozolomide 1399
TERT-CLPTMIL 1001
 testicular cancer 1833
 testicular germ cell tumour 1754, 1853
 TFT 429
 TGF- β -activated kinase-1 129
 the Glasgow Prognostic Score 988
 The Netherlands 12
 therapeutic target 63
 third primary cancer 549
 thymosin beta 15 1892
 thyroid 994
 TIGAR 516
 time trends 1159
 tissue damage 1534
 tissue factor 1125
 tissue microarray 482
 tobacco 1618
 topoisomerase 2 108
 toxic death 1
 toxicity 158, 308
 TP53 mutation 1138
 TP53 mutation status 1722
 TPI 429
 traditional Chinese medicine 411
 trastuzumab 956, 1075
 TRC 724
 treatment 12, 1901
 treatment response 1684
 triage 617
 triple-negative breast cancer 75, 1892
 trust 1938
 tumour angiogenesis 1853
 tumour burden 1518
 tumour burden and metastasis 501
 tumour immunology 1729
 tumour inflammatory cell infiltrate 864
 tumour margin 462
 tumour necrosis factor alpha (*TNF α*). 748
 tumour regression 516
 tumour suppression 315
 tumour suppressor 967
 tumour xenograft 315
 tumour-initiating cells 462
 tyrosine kinase inhibitors 1227

 ultrasound 224, 469
 United Kingdom 1195, 1467
 uranium miners 1188
 urinary bladder neoplasms 1589
 urine 123
 urothelial carcinoma 1384
 US Veterans Affairs 195
 utility 778

 validation 260
 vascular endothelial growth factor signalling 1722
 vascular targeting agent 37
 vatalanib 1044
 VE-821 291
 VEGF 961, 1207, 1481, 1702, 1869
 VEGF trap 598
 VEGF-A 700, 977
 VEGFR2 1044
 VEGFR-2 1869
 venous thromboembolism 612
 vinorelbine 442, 823
 visual inspection with acetic acid (VIA) 772
 vitamin D 158
 vitamin D binding protein 1589

 whole sentinel lymph node 1239
 WNT pathway 1144
 wound healing 961

 young age 382
 zoledronic acid 7